Congrats to Lawrence Phillips and ASNC Society
Larry is an outstanding clinician and leader
Glenn Fishman Jennifer H. Mieres, MD , FACC, MASNC, FAHA Sharmila Dorbala Gregory S Thomas MD Mouaz Al-Mallah, M.D MSc

Don’t miss #CVInflammationCME24 ! Packed with informative & practical guidance on the clinical management of #cardiovascular complications in #autoimmune conditions & #inflammation in CVD.

Jointly organized with Brigham and Women's Hospital

Learn more: bit.ly/3tzYJHY

#cardiorheum

Inflammation, Atherosclerosis, and Ischemic Events -Exploring the Hidden Side of the Moon NEJM nejm.org/doi/full/10.10… love rereading 1997 editorial by Attilio Maseri - very clear to him >25 yrs ago Giuseppe Biondi-Zoccai Brittany Weber Dr. Michael Garshick Benjamin Van Tassell Giovanna Liuzzo EHJ Editor-in-Chief

Thanks Sam Tsimikas, MD for highlighting our poster, and congrats to Donya Mazdeyasnan MS2 UC San Diego School of Medicine for leading this

AHA Science
UC San Diego Cardiology Harpreet Bhatia Pam R. Taub, MD❤️💃🏻 Erin D. Michos, M.D. Michael D. Shapiro Christie Ballantyne Dr. Michael Garshick Eugenia Gianos MD Lori Daniels

Brittany Weber Dr. Michael Garshick Jon T Giles Elaine Husni Ron Blankstein Marcelo Di Carli Kat Liao Joseph F. Merola, MD MMSc Congratulations to my cardio-rheum friends Brittany Weber and Dr. Michael Garshick on your amazing #ACR23 symposium 💥❤️

NYU Langone cardiologist Michael Garshick, MD and cardiologist Brittany Weber, MD, PhD from Brigham and Women’s Cardiovascular Life Science attend #acr23 . Collaborators and Co-Course Directors for our annual cardio-inflammation CME, Dr. Garshick and Dr. Weber presented posters in the growing specialty of #cardiorheum .

Looking forward to Late Breaking Science at #AHA2023 - Multicenter, international, phase II clinical trial of IL-1 blocker, Goflikicept (R-PHARM), in patients with STEMI: is quenching of the acute inflammatory response with IL-1 blockers a class effect? AHA Science AHAMeetings

𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗡𝗲𝘄𝘀! Are JAK inhibitors associated with higher risk of all-cause mortality, #MACE , and #VTE when used for a #dermatology indication?

Learn more via JAMA Dermatology ➡️bit.ly/49hKgjL

#CardioTwitter #CVD

Learning about lipoprotein (a) Apheresis from ⁦Michael Wilkinson⁩

Excellent talk by Dr. Michael Garshick at National Lipid Association CLU 2023, residual risk of inflammation in ASCVD. An exciting area for study: relationship between inflammation and conditions like obesity, DM, autoimmune diseases, Lp(a)
NYU CVD Prevention Christie Ballantyne Michael D. Shapiro UC San Diego Cardiology

Nyu at the NLA. ⁦NYU CVD Prevention⁩ ⁦NYU CVD Prevention⁩ ⁦Dr. James Underberg⁩

This is a 'must read' - Cardiovascular Risk Management in Patients Treated with JAK inhibitors Journal of Cardiovascular Pharmacology journals.lww.com/cardiovascular… Brittany Weber Dr. Michael Garshick International Cardio-Oncology Society

Sore, Hot, and at Risk: The Emerging Specialty of Cardio‐Rheumatology | Journal of the American Heart Association. Proud to be a part of this collaboration. ⁦AntonioAbbate⁩ ⁦Brittany Weber⁩ ahajournals.org/doi/10.1161/JA…

⭐️Fantastic opening session #NLAsessions Foundation of the NLA National Lipid Association Drs. Libby and Ridker, update on atherosclerosis and inflammation. Pam R. Taub, MD❤️💃🏻 Michael D. Shapiro Erin D. Michos, M.D. Dr. Michael Garshick UC San Diego Cardiology Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Christie Ballantyne

New content online! Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease dlvr.it/SpcmP3

Pam R. Taub, MD❤️💃🏻 Michael D. Shapiro National Lipid Association Dr. James Underberg Alan Brown MD MHA FACC FNLA Harpreet Bhatia Matthew Budoff MD Family Heart Foundation Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Christie Ballantyne Amit Khera Seth Martin Erin D. Michos, M.D. Dr. Michael Garshick Amit V. Khera Pradeep Natarajan Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 UC San Diego Health Nishant Shah, MD Salim Virani Katherine Wilemon

Another great study demonstrating that rapid CAC progression is associated with all-cause mortality. If CAC is progressing, more needs to be done. This is not just 'statin' effect of increased density, rapid progression infers worsening atherosclerosis pubmed.ncbi.nlm.nih.gov/37102229/

From @jaccjournals jacc.org/doi/10.1016/j.…
Very nice figure, central role of IL-1 identified in this link between inflammation and cardiac injury and dysfunction - unfortunately no mention of protective role of recombinant IL-1 receptor antagonist, anakinra.